TMED1

Across TCGA pan-cancer cohorts, TMED1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of TMED1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TMED1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TMED1 is over-expressed in tumor, although a few such as THCA and KIRP show the opposite, repressed pattern.

HNSC, COAD, and LIHC are the cancer types where TMED1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMED1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.788	<.001	12	view →
COAD	All	IV	+0.992	<.001	11	view →
LIHC	All	III,IV	+0.689	<.001	9	view →
BLCA	All	All	+0.483	.004	5	view →
THCA	Male	II,III,IV	−0.391	.001	5	view →
STAD	All	II,III,IV	+0.602	.001	4	view →
CHOL	Female	All	+1.390	<.001	3	view →
KIRP	Male	All	−0.315	.021	1	view →
LUSC	Male	All	+0.216	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

TMED1–HNSC

Open the HNSC breakdown →